Pfizer’s COVID-19 vaccine earned about $37 billion in sales in 2021, the product’s first full year on the market, while revenue predictions for 2022 fell short of analysts’ expectations, sending the company’s stock down over 5%. Pfizer claimed in its latest quarterly earnings report released Feb. 8 that the company’s two-dose COVID-19 vaccine, dubbed Comirnaty, produced $36.78 billion in revenue for 2021. (pdf). Pfizer’s full-year revenue in 2021 was $81.3 billion, up 92 percent from the previous year. Without the contributions from Comirnaty and Pfizer’s COVID-19 antiviral medication Paxlovid, revenues increased by only 6% to $44.4 billion for the year. Pfizer’s Chief Financial Officer, Frank D’Amelio, stated in a statement, “We just concluded a year where we provided tremendous value to society, including to both patients and shareholders,” “We exceeded our goal of delivering 3 billion doses of Comirnaty in … Continue reading Pfizer’s Pandemic Revenue is Appalling, and the Left is Blind to the Paper Trail